|
|
Lamisil Class Action Lawsuits Information
Indicated for adjunctive therapy of partial seizures in
adults with epilepsy, Lamictal is an antiepileptic drug. A boxed warning was
added to Lamictal labeling in March 1997 including reports of severe,
potentially life-threatening rash, including Stevens-Johnson syndrome and toxic
epidermal necrolysis.
In addition, the revised Lamictal labeling emphasized Lamictal is not indicated
for use in patients below the age of 16 years. Lamictal pediatric patients had a
higher risk of developing a potentially life-threatening rash. At the time of
the Lamictal revised labeling there were an estimated 600,000 patients.
At the start of 2003, GlaxoSmithKline announced a labeling change was being made
for Lamictal. Lamictal is now indicated in patients as young as two years with
epilepsy as adjunctive therapy for partial seizures, as well as for generalized
seizures of Lennox-Gastaut syndrome. Despite this Lamictal labeling change,
safety and effectiveness for Lamictal patients under 16 years of age has not yet
been established other than those with partial seizures and the generalized
seizures of LGS.
In June 2003, GlaxoSmithKline's Lamictal became the first medication since the
introduction of Lithium to be approved for the long-term treatment of bipolor
disorder. The Lamictal announcement marks a significant change in bipolar
treatment, but the effectiveness of Lamictal in the acute treatment of mood
episodes has not yet been recognized.
Warnings on Lamictal labeling also include reports of hypersensitivity reactions
that have included fatal or life-threatening instances. Any signs of a rash
while using Lamictal should result in the immediate discontinuation of Lamictal
until a qualified physician has been consulted.
Lamisil Side Effects
Lamictal side effects are serious and life-threatening
conditions. Since there is a much greater risk of occurring in young patients,
Lamictal is not permitted for patients 16 years and younger. Young Lamictal
patients had suffered potentially fatal rashes that caused the FDA to eventually
change the Lamictal labeling to better reflect the risks of the deadly Lamictal
side effects.
The Lamictal side effects have been added to Lamictal labeling in a boxed
warning as of March 1997. Lamictal side effects were so serious that the FDA had
the boxed warning added to include reports of severe, potentially
life-threatening rash, including Stevens-Johnson syndrome and toxic epidermal
necrolysis. In addition, prescription errors have occurred with Lamictal
antiepileptic drug and Lamisil anti-fungal drug, greatly increasing the chances
of suffering Lamictal side effects and Lamisil side effects.
More Lamisil Information
Lamictal drug was created as an adjunctive therapy of partial
seizures in epileptic adults. The Lamictal drug was on the market for a while
before the FDA had a boxed warning added to the Lamictal drug labeling after
reports of deadly side effects were made. Side effects of Lamictal drug included
reports of severe, potentially life-threatening rash, including Stevens-Johnson
syndrome and toxic epidermal necrolysis.
The potentially deadly rashes were found to have a higher risk of occurrence in
pediatric Lamictal drug patients, and now Lamictal drug is not prescribed for
patients 16 years and younger. Now, Lamictal drug has been used to help treat
the antidepressant activity in patients with bipolar disorder. All patients
should first be evaluated to determine if Lamictal drug benefits would outweigh
the risks.
For more free legal information on known dangerous drugs and Class Action Lawsuits, please use the
links below:
|
